PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 118 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2021. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $2,300,000 | -25.9% | 756,675 | +70.8% | 0.02% | -28.6% |
Q3 2021 | $3,106,000 | +87.0% | 443,081 | +144.9% | 0.02% | +90.9% |
Q2 2021 | $1,661,000 | -2.2% | 180,944 | +3.6% | 0.01% | -15.4% |
Q1 2021 | $1,698,000 | +59.9% | 174,693 | +68.7% | 0.01% | +44.4% |
Q4 2020 | $1,062,000 | +0.7% | 103,528 | -1.0% | 0.01% | -18.2% |
Q3 2020 | $1,055,000 | -7.0% | 104,543 | -3.8% | 0.01% | -8.3% |
Q2 2020 | $1,134,000 | +61.1% | 108,689 | +30.3% | 0.01% | +33.3% |
Q1 2020 | $704,000 | -36.2% | 83,445 | -33.9% | 0.01% | -18.2% |
Q4 2019 | $1,104,000 | -2.1% | 126,175 | +20.4% | 0.01% | -21.4% |
Q3 2019 | $1,128,000 | +131.1% | 104,820 | +173.3% | 0.01% | +100.0% |
Q2 2019 | $488,000 | -71.1% | 38,360 | -12.0% | 0.01% | -70.8% |
Q1 2019 | $1,690,000 | +373.4% | 43,580 | +148.5% | 0.02% | +300.0% |
Q4 2018 | $357,000 | +49.4% | 17,540 | +236.7% | 0.01% | +100.0% |
Q3 2018 | $239,000 | -66.9% | 5,210 | -28.6% | 0.00% | -76.9% |
Q4 2017 | $721,000 | – | 7,297 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |